AlmutairiAR, ZhouL, GelladWF, et al.Effectiveness and safety of non-vitamin k antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: A systematic review and meta-analyses. Clin Ther. 2017; 39(7):1456–1478.e36; doi: 10.1016/j.clinthera.2017.05.358
2.
CarliG, FarsiA, ChiariniF, et al.Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal. Eur Ann Allergy Clin Immunol. 2019; 51(1):7–14.
3.
CortelliniG, CarliG, FranceschiniL, et al.Evaluating nonimmediate cutaneous reactions to non-vitamin K antagonist oral anticoagulants via patch testing. J Allergy Clin Immunol Pract. 2020; 8(9):3190–3193; doi: 10.1016/j.jaip.2020.04.055
4.
KhanFY, SulaimanTO. Anaphylaxis following rivaroxaban ingestion: Report of an extremely rare case. Pan Afr Med J. 2021; 38:333.
5.
PhillipsEJ, BigliardiP, BircherAJ, et al.Controversies in drug allergy: Testing for delayed reactions. J Allergy Clin Immunol., 2019; 143(1):66–73.
6.
CortelliniG, RossiF, LippolisD, et al.Delayed hypersensitivity to new oral anticoagulants. Demonstration of cross reactivity for the drug category and definition of non-irritant concentrations for patch tests. Eur Ann Allergy Clin Immunol. 2019; 51(1):38–40.
7.
Tomás-PérezM, De Las VecillasL. Allergy to rivaroxaban: A case report showing cross-reactivity with other direct anticoagulants and the role of the basophil activation test. J Investig Allergol Clin Immunol. 2023; 33(5):405–406; doi: 10.18176/jiaci.0883
8.
HampelA, KinaciyanT. Docetaxel-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) confirmed by skin testing. Contact Dermatitis. 2024; 90(5):525–527; doi: 10.1111/cod.14505
9.
NespoulousL, MateiI, CharissouxA, et al.Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. Contact Dermatitis. 2018; 79(6):378–380; doi: 10.1111/cod.13084
10.
PatilT, IkekwereC. A case report of rivaroxaban-induced urticaria and angioedema with possible cross-reaction to dabigatran. J Med Cases. 2019; 10(12):359–363.
